Abstract Details

Title Survival Benefit of Glioblastoma Patients after FDA Approval of Temozolomide and Bevacizumab: A Population-Based Study

Topic Neuro-oncology

Presentation(s) P1 - (-)

Poster/Presentation
Number 168

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Jay-Jiguang Zhu, MD, PhD, FAAN (Univ of Texas Health Science Center in Houston)	The institution of Dr. Zhu has received research support from Novocure, Inc. The institution of Dr. Zhu has received research support from ABM Therapeutics Corporation . The institution of Dr. Zhu has received research support from Chimerix Inc.

��ɫ��